Search Within

Neil Jayendra Shah

  1. "Computational Oncology Service"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Center for Molecular Imaging and Biotechnology (CMIB) (6)
  2. Computational Oncology Service (6)
  3. Department of Medicine (6)
  4. Epidemiology and Biostatistics (6)
  5. GSK Faculty (6)
  6. Genitourinary Oncology Service (6)

More Groups

People
  1. Martin Voss (6)
  2. Ritesh Kotecha (6)
  3. Robert Motzer (6)
  4. Andrea Knezevic (5)
  5. Chung-Han Lee (5)
  6. Darren Feldman (5)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (1)
  4. 2021 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer (1)
  3. European Urology Oncology (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier BV (1)
  3. Wiley Blackwell (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer
    Journal Article

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Chaim, J.; Chen, Y.; Jacobi, R.; Zucker, M.; Reznik, E.; McHugh, D.; Shah, N. J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save
  • Genomic ancestry in kidney cancer: Correlations with clinical and molecular features
    Journal Article

    Kotecha, R. R.; Knezevic, A.; Arora, K.; Bandlamudi, C.; Kuo, F.; Carlo, M. I.; Fitzgerald, K. N.; Feldman, D. R.; Shah, N. J.; Reznik, E.; more...
    Cancer (2024)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214
    Meeting Abstract

    Voss, M. H.; Shah, N. J.; Kalvin, H. L.; Lihm, J.; Li, H.; Kotecha, R. R.; Jarchum, I.; Vemula, S. V.; Gupta, S.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates
    Journal Article

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Zucker, M.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Dadoun, C.; Reznik, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save